Connect with us

News

‘First Mover to Game Changer’: Celltrion announces 2020-2030 strategy at the 38th J.P. Morgan Healthcare Conference

gbafNews28

Celltrion today announced the companys vision for the next decade at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, USA. Celltrions Chairman Jung Jin Seo outlined the companys strategic transition: Celltrion expects to transform from a ˜first mover to a ˜game changer by 2030.

Celltrions strategy is anticipated to differentiate the company in the biosimilars landscape, building on its existing portfolio of treatments, including value added medicines or bioinnovatives such as Remsima SC, the worlds first subcutaneous formulation of infliximab. Remsima SC has the potential to offer an alternative personalised and convenient treatment option and was approved by the European Commission for patients with rheumatoid arthritis in November 2019. Celltrion Healthcare, the distribution arm of Celltrion, has also applied for a further extension to the marketing authorization of Remsima SC, to include the inflammatory bowel disease indication. This approval decision is expected in mid-2020.

Jung Jin Seo, Celltrions Chairman, said ˜˜Celltrion boasts a strong and dynamic product portfolio and pipeline. As we chart the companys 2030 vision, the company hopes to launch one biosimilar product every year, reaching a total number of 18 products by 2030. Biosimilars and value added medicines which we call ˜bioinnovatives (innovative biosimilars) are set to be our key growth drivers in 2020. We plan to enter the new drugs and ubiquitous-healthcare business sector towards 2030.

Celltrion expects a number of significant factors will positively influence biosimilar uptake and the companys growth in the coming years, including healthcare budgetary pressures; growing demand for low-cost alternative medicines and an increase in prescriptions for biologics. These factors have played a role in the growth of the biosimilar industry in recent years. Celltrions Chairman highlighted that increasingly positive sentiment from key stakeholders has contributed to Celltrion Healthcares growth in sales over the course of 2019 and is set to continue.

As demonstrated by the findings of a recent report from healthcare consulting firm IQVIAi, the companys market share in major European markets has continued to grow. Remsima, the worlds first approved monoclonal antibody biosimilar has continued to overtake the market share of its reference drug, Janssens Remicade, with Remsima owning 59% of the market. Celltrion has also seen growth in the uptake of its rituximab biosimilar, Truxima and trastuzumab biosimilar, Herzuma, with their market shares reaching 38% and 15% respectively. These figures place Truxima and Herzuma as the leading biosimilars in terms of market share within the rituximab and trastuzumab markets.

Ho Ung Kim, Head of the Medical and Marketing Division at Celltrion Healthcare said, As a ˜first mover, Celltrion Healthcare has gained extensive experience in the biopharmaceutical field and is now ready to initiate a direct sales model. Celltrion Healthcare has set up its own sales network and overseas offices in 14 countries throughout Europe to secure price competitiveness, and strives to lead the global tumour necrosis factor alpha (TNF-α) inhibitors market with its innovative infliximab Remsima SC, which is projected to be worth approximately $50 billion.

As Celltrion enters the next decade, its ambitions reach beyond biosimilars and into new drug development. At the conference, Jung Jin Seo also outlined the companys new drug development plan which is set to combine new platform technology and drug repositioning. This platform technology – the Antibody Delivery Enhancing Domain – is designed to increase the delivery efficiency of antibody-drug conjugates and their cell penetration, which has the potential to enhance cancer treatments. The company is set to create a new paradigm following innovation trends throughout the healthcare sector from 2020 to 2030.

– ENDS –

Notes to Editors:

About Celltrion Healthcare

Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 120 different countries. For more information please visit: https://www.celltrionhealthcare.com/en-us

About CT-P13 (biosimilar infliximab)ii,iii,iv

CT-P13 is developed and manufactured by Celltrion, Inc. and was the worlds first monoclonal antibody biosimilar approved by the European Commission (EC). It is indicated for the treatment of eight autoimmune diseases including RA and IBD. It was approved by the EC under the trade name Remsima in September 2013 and launched in major EU countries in early 2015. The U.S. Food and Drug Administration approved CT-P13 in April 2016 under the trade name Inflectra. CT-P13 is approved in more than 89 countries (as of January 2020) including the US, Canada, Japan and throughout Europe.

CT-P13 IV is usually given as 3mg per kg/body weight in RA and as 5mg per kg/body weight for the other indications. Infliximab IV is given as an infusion over two hours. All patients are monitored for any reactions during the infusion and for at least one to two hours afterwards. Celltrion has also developed a subcutaneous (SC) formulation of infliximab that has three administration options; via a pre-filled pen (auto injector), pre-filled syringe or pre-filled syringe with needle safeguard. The SC formulation has the potential to enhance treatment options for the use of infliximab biosimilar by providing high consistency in drug exposure and a convenient method of administration.

CT-P13 SC has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and EU marketing authorisation for the treatment of people with RA. A phase III study of CT-P13 SC for people with inflammatory bowel disease (IBD) is underway. Celltrion has submitted a further variation to the marketing authorization of CT-P13 SC to extend the indication to inflammatory bowel disease. In the United States, Remsima SC will be reviewed through the new drug pathway with the expectation of receiving US Food and Drug Administration (FDA) approval by 2022.

About ˜bioinnovatives

˜Bioinnovatives are defined by Celltrion Healthcare as ˜innovative biosimilars. The term derives from the combination of the words ˜biosimilar and ˜innovation.

While biosimilars, as the term suggests, aim to establish similarity to a known biologic; Celltrion Healthcare considers ˜bioinnovatives as ˜value added medicines. Medicines for Europe define ˜value added medicines as biosimilars which address additional healthcare needs and deliver relevant improvements for patients, healthcare professionals and/or payers. The ˜added value may be achieved through finding a new indication (drug repositioning), finding a better formulation or dosage (drug reformulation), or developing a combined drug regimen, adding a new device or providing a new service (drug combination). Relevant improvements include: a better efficacy, safety and/or tolerability profile; a better method of administration and/or ease of use; and new therapeutic uses (indication/population).v

References


i IQVIA WRP 2019. Data on File.

ii Yoo DH, Jaworski J, Matyska-Piekarska E et al. A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: One Year Results from Part One of a Phase I/III Randomised Controlled Trial in Patients with Rheumatoid Arthritis. Poster (FRI0128) Presented at EULAR 2019.

iii Westhovens R, Wiland P, Zawadzki M et al. A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 30-week Results from Part Two of a Phase I/III Randomised Controlled Trial in Patients with Rheumatoid Arthritis. Poster (SAT0170) Presented at EULAR 2019.

iv European Medicines Agency Summary of Product Characteristics (SmPC). CT-P13. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002576/WC500150871.pdf [Last accessed January 2020].

v European Medical Advisory Board on Value Added Medicines. Perceptions and recommendations of physicians/ KOLs on value added medicines. 2019. Available at https://www.medicinesforeurope.com/wp-content/uploads/2019/11/Advisory-board_report-exec-summary_final.pdf [Last accessed January 2020]

Zuzanna Grzeskiewicz

[email protected]

+44 (0) 7506 339043

Preetika Ramjoorawon

[email protected]

+44 (0) 7595700045

News

Putnam Announces Dividend Rates for Open-End Funds

gbafNews28

The Trustees of The Putnam Funds have declared the following distributions today.

 

RECORD

PAYMENT

FUND NAME AND DISTRIBUTIONS

DATE

DATE

 

Putnam Growth Opportunities Fund “ Class A Shares (POGAX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class B Shares (POGBX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class C Shares (POGCX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R Shares (PGORX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class Y Shares (PGOYX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R5 Shares (PGODX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Growth Opportunities Fund “ Class R6 Shares (PGOEX)

$1.7200 per share long-term capital gain

12/4/20

12/8/20

 

Putnam Multi-Cap Core Fund “ Class A Shares (PMYAX)

$0.2580 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.6580 per share total

 

Putnam Multi-Cap Core Fund “ Class B Shares (PMYBX)

$0.0370 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.4370 per share total

 

Putnam Multi-Cap Core Fund “ Class C Shares (PMYCX)

$0.0470 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.4470 per share total

 

Putnam Multi-Cap Core Fund “ Class R Shares (PMYZX)

$0.1490 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.5490 per share total

 

Putnam Multi-Cap Core Fund “ Class Y Shares (PMYYX)

$0.3210 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.7210 per share total

 

Putnam Multi-Cap Core Fund “ Class R6 Shares (PMYTX)

$0.3510 per share investment income

12/4/20

12/8/20

$0.4000 per share long-term capital gain

$0.7510 per share total

 

Putnam Research Fund “ Class A Shares (PNRAX)

$0.2360 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.8080 per share total

 

Putnam Research Fund “ Class B Shares (PRFBX)

$0.1630 per share short-term capital gain

12/4/20

12/8/20

$0.4090 per share long-term capital gain

$0.5720 per share total

 

Putnam Research Fund “ Class C Shares (PRACX)

$0.1630 per share short-term capital gain

12/4/20

12/8/20

$0.4090 per share long-term capital gain

$0.5720 per share total

 

Putnam Research Fund “ Class R Shares (PRSRX)

$0.1470 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.7190 per share total

 

Putnam Research Fund “ Class Y Shares (PURYX)

$0.3130 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.8850 per share total

 

Putnam Research Fund “ Class R6 Shares (PLJMX)

$0.3710 per share investment income

12/4/20

12/8/20

$0.1630 per share short-term capital gain

$0.4090 per share long-term capital gain

$0.9430 per share total

 

Putnam Small Cap Growth Fund “ Class A Shares (PNSAX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class B Shares (PNSBX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class C Shares (PNSCX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class R Shares (PSGRX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class Y Shares (PSYGX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Growth Fund “ Class R6 Shares (PLKGX)

$0.9100 per share short-term capital gain

12/4/20

12/8/20

$2.4300 per share long-term capital gain

$3.3400 per share total

 

Putnam Small Cap Value Fund “ Class A Shares (PSLAX)

$0.1030 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class B Shares (PSLBX)

$0.0430 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class C Shares (PSLCX)

$0.0750 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R Shares (PSCRX)

$0.0780 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class Y Shares (PYSVX)

$0.1240 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R5 Shares (PSLRX)

$0.1330 per share investment income

12/4/20

12/8/20

 

Putnam Small Cap Value Fund “ Class R6 Shares (PSCMX)

$0.1450 per share investment income

12/4/20

12/8/20

 

Putnam Sustainable Future Fund “ Class A Shares (PMVAX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class B Shares (PMVBX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class C Shares (PMPCX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class R Shares (PMVRX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class Y Shares (PMVYX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Future Fund “ Class R6 Shares (PNOTX)

$1.0840 per share short-term capital gain

12/4/20

12/8/20

$1.4400 per share long-term capital gain

$2.5240 per share total

 

Putnam Sustainable Leaders Fund “ Class A Shares (PNOPX)

$0.3320 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.3400 per share total

 

Putnam Sustainable Leaders Fund “ Class B Shares (PNOBX)

$0.4740 per share short-term capital gain

12/4/20

12/8/20

$7.5340 per share long-term capital gain

$8.0080 per share total

 

Putnam Sustainable Leaders Fund “ Class C Shares (PNOCX)

$0.4740 per share short-term capital gain

12/4/20

12/8/20

$7.5340 per share long-term capital gain

$8.0080 per share total

 

Putnam Sustainable Leaders Fund “ Class R Shares (PNORX)

$0.1340 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.1420 per share total

 

Putnam Sustainable Leaders Fund “ Class Y Shares (PSLGX)

$0.5920 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.6000 per share total

 

Putnam Sustainable Leaders Fund “ Class R6 Shares (PNOYX)

$0.6910 per share investment income

12/4/20

12/8/20

$0.4740 per share short-term capital gain

$7.5340 per share long-term capital gain

$8.6990 per share total

 

PUTNAM SHAREHOLDERS CONTACT: 1-800-225-1581

Continue Reading

News

The Public Relations Network (Asia Chapter) to offer regional intelligence & local expertise to industries benefiting from the recently-signed RCEP amid COVID-19 Challenges

gbafNews28

HONG KONG SAR – Media OutReach – 30 November 2020 – With the signing of the Regional Comprehensive Economic Partnership (RCEP) on 15 November 2020, the Asia Chapter members of Public Relations Network (PRN) are prepared to provide all-round and cross-border support to various industries from participating nations of RCEP in regards of business development and investment.

PRN Asia Chapter is formed by profound local PR agencies across Asia. With this tightly-knit network of PR experts, chapter members align to provide effective, efficient, and think-out-of-the-box solutions across the region. With all local teams on board, PRN Asia Chapter is well-positioned to offer hands-on and ready-to-deploy services, from media relations and digital campaigns, to event management and crisis communications to industries who will blossom as a result of the RCEP.

Under the impact of COVID-19, demand for public relations solutions has risen to new height. With all kinds of new normal in place, being highly-flexible and mobile, the ability to mobilize regional connections swiftly and to establish new game plans as a result of changing market demands are all crucial to enterprises.

Ms Belinda Chan, Chairperson of the PRN Asia Chapter, and Managing Partner of Creative Consulting Group in Hong Kong: “The RCEP will drive the shift of economic engine to Asia. With our strong foothold in strategic locations across the region, we, together, represent a one-of-a-kind PR think-tank for enterprises that are drawn to tap into the market benefits.”

Mr Jacky Cheng, CEO of CommNow in Shanghai: “This RCEP can help China building closer trade relations with Asian countries, which will eventually help Chinese companies to find their new markets. This is very crucial under the current circumstances.”

Ms Stacy Ang, Director of The Right Spin in Singapore: “The RCEP has unlocked new levels of market access in Asia. As agencies that can move expeditiously in our own markets while implementing cross-border plans collectively, our network offers the desired nimbleness, synergy and competence for businesses to spread their wings and capture opportunities as they emerge.”

Ms Sharon Wu, Managing Director of SWEM Consulting Group in Taipei: “Although Taiwan have not become RCEP members, but Taiwan government have very good tax policies for import trade between Japan and ASEAN countries. We believe Taiwan and Asia-Pacific brands can depend on PRN Asia members support and RCEP policy, win more business successful and more opportunities for brand grow up in the future.”

Ms Sarah Song, Managing Director of Integra Communications in Seoul: “We will work together more closely and strengthen our network with cooperation and synergy in terms of communication through RCEP. Our role as an Asian network will bring our professionalism and creativity to form a solid partnership and new perspectives to work in a new era that will grow with future economic development.”

Ms Pacharee Pantoomano, Managing Director of Brandnow.asia in Bangkok: “RCEP will undoubtedly create economic vibe within the region and now is definitely the right time to make an entry into the market. With our strong base in Thailand and in Asia as part of PRN, we can offer market consultation and research as well as business matching to clients at large. With local intelligence in place, we aim to enable clients to benefit from RCEP more effectively and cost-efficiently.”

Ms Clāra Ly-Le, Managing Director of EloQ Communications in Ho Chi Minh City: “I am proud that this RCEP partnership was signed at the ASEAN Summit hosted in my country Vietnam. I have high hopes in this partnership and expect that it will help many industries recover from the COVID-19 crisis. As a member of PRN Asia Chapter, we are proud to work with fellow members to deliver top-notch services for clients from countries coming from the RCEP, from market entry to well-rounded integrated marketing campaigns.”

About Public Relations Network (PRN)

Public Relations Network (PRN) is a global collective of like-minded, owner-managed Public Relations agencies providing consultancy and local support for international PR campaigns. PRN has agency members in Austria, Brazil, Canada, China — Mainland, China — Hong Kong, Czech Republic, Denmark, Finland, France, Germany, Greenland, Italy, Mexico, Morocco, Panama, Poland, Portugal, Singapore, Slovakia, South Korea, Spain, Switzerland, Taiwan, Thailand, the UK, the USA, and Vietnam. For more info, please visit: www.pr-network.biz.

Continue Reading

News

Zane Morton to oversee DHL Global Forwarding in New Zealand and Fiji

gbafNews28

  • The logistics veteran brings four decades of DHL experience to the key role in the South Pacific

SINGAPORE – Media OutReach – 1 December 2020 – As the business in DHL Global Forwarding New Zealand and Fiji continue on its growth trajectory, the freight specialist of the Deutsche Post DHL Group officially appoints Zane Morton as Managing Director for these two countries in the South Pacific effective today. Having built an illustrious career with the Group spanning almost four decades, Morton will lead the operations in New Zealand and oversee the growth of the business in Fiji, managed by Country Manager Ray Viegas, who will report to him.

[View Image]

 

“Across his many different roles and responsibilities, Zane has proven himself to be a respected leader, who is customer-oriented in his outlook and finely attuned to developments in the logistics and freight forwarding industry. We are confident he will help our businesses in New Zealand and Fiji reach greater heights amidst the current challenging microenvironment and augment existing synergies between our operations in New Zealand and Fiji,” said Charles Kaufmann, CEO, DHL Global Forwarding North Asia South Pacific.

 

New Zealand’s exports grew 58.6% in the last decade between 2009 and 2019. DHL Global Forwarding is optimistic about the growth potential in the market and considers perishables, life sciences and healthcare, amongst others, as promising areas that the company would further develop.

 

Reporting to Kaufmann in this new role, Morton said, “I’m acutely aware that I’m taking on the role at a very interesting time. In the short term, the industry will face a massive undertaking of delivering an unprecedented volume of more than 10 billion doses of vaccines worldwide; at the same time, DHL Global Forwarding is undergoing a digital transformation with the rollout of myDHLi in accordance to the Group’s Strategy 2025 to futureproof the organization and improve operational excellence in the long term. I am excited to lead the teams in New Zealand and Fiji to take on these challenges and leverage the opportunities to bring the business to greater heights.”

 

DHL recently published a white paper on securing a stable supply chain for vaccines and medical goods during health crises and how the transport of vaccines as a highly temperature-sensitive product can be managed effectively to combat the further spread of the COVID-19 virus. The global logistics leader has been serving the life science and healthcare sector for over 20 years, shipping all sorts of pharmaceutical and medical-related products, including vaccines and therapeutics, worldwide.

 

Morton first joined DHL in New Zealand in 1983 and held various positions during his career, including Operations Management, Country Sales & Marketing Manager, Country Ocean Freight Manager and Wellington Branch Manager. In 2006, he relocated to Dubai where he was the Regional Marketing and Sales Manager for DHL Middle East and Africa for DHL Global Forwarding. He returned to New Zealand in 2011 and was appointed Head of Ocean Freight in 2012, and subsequently named Head of Sales in 2015.

 

Note to editors:

The New Zealand- Europe FTA represents an opportunity to gain better access to the bloc’s almost 500 million consumers through lower tariffs, and new multi-modal shipping options could also lead to even more savings for importers. Read more on DHL’s Logistics of Things.


DHL – The logistics company for the world

DHL is the leading global brand in the logistics industry. Our DHL divisions offer an unrivalled portfolio of logistics services ranging from national and international parcel delivery, e-commerce shipping and fulfillment solutions, international express, road, air and ocean transport to industrial supply chain management. With about 380,000 employees in more than 220 countries and territories worldwide, DHL connects people and businesses securely and reliably, enabling global sustainable trade flows. With specialized solutions for growth markets and industries including technology, life sciences and healthcare, engineering, manufacturing & energy, auto-mobility and retail, DHL is decisively positioned as “The logistics company for the world”.

DHL is part of Deutsche Post DHL Group. The Group generated revenues of more than 63 billion euros in 2019. With sustainable business practices and a commitment to society and the environment, the Group makes a positive contribution to the world. Deutsche Post DHL Group aims to achieve zero-emissions logistics by 2050.

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News48 mins ago

Putnam Announces Dividend Rates for Open-End Funds

The Trustees of The Putnam Funds have declared the following distributions today.   RECORD PAYMENT FUND NAME AND DISTRIBUTIONS DATE...

gbafNews28 gbafNews28
News50 mins ago

2021 skincare solutions just a click away with POND’S Skin Advisor Live chatbot now on Shopee

Banish Pandemic-induced Skincare Woes with POND’s Beauty Tech on Shopee   HO CHI MINH CITY, VIETNAM – Media OutReach – 1 December...

gbafNews28 gbafNews28
News50 mins ago

Consumer spending in Islamic economy sectors forecast to rebound by end-2021, market size slated to reach US$2.3 trillion by 2024

Takeaways from the State of the Global Islamic Economy Report 2020/21 will be unveiled at Reimagine: Halal in Asia 2020,...

gbafNews28 gbafNews28
News50 mins ago

Infor Launches Hospitality Management Cloud Solution based on Amazon Web Services in China to Spur Digital Transformation among Chinese Hotels

Rich capabilities allow hoteliers to centralize cross-platform hospitality management systems; AWS partnership ensures stability and security of data in the...

gbafNews28 gbafNews28
News50 mins ago

Zipline, Medical Drone Delivery Pioneer to Headline HISA2020

JOHANNESBURG, SOUTH AFRICA – Media OutReach – 30 November 2020 – Technology is transforming industries on a global scale, with the COVID-19 pandemic...

gbafNews28 gbafNews28
News50 mins ago

“Emma by AXA”, your insurance and healthy living partner Download now to enjoy first-in-market free “Post-Vaccination Protection”

HONG KONG SAR – Media OutReach – 30 November 2020 – Emma by AXA — AXA‘s all-in-one insurance & health services platform...

gbafNews28 gbafNews28
News50 mins ago

Lee Kum Kee Sauce Group Appoints Ms. Katty Lam as Chief Executive Officer

HONG KONG SAR – Media OutReach – 1 December 2020 – Lee Kum Kee Sauce Group announces the appointment of Ms. Katty Lam...

gbafNews28 gbafNews28
News50 mins ago

Salaries set to rise in 2021, but employers in the Philippines signal increased caution, says Mercer survey

Companies forecast a 5.6% overall increase in salaries for 2021, but more than half say they expect changes to salary...

gbafNews28 gbafNews28
News50 mins ago

Blake Dair Announces New Managing Partner

SINGAPORE – Media OutReach – 1 December 2020 – Blake Dair Consulting Pte Ltd, the Singapore based front office trading and technology specialist...

gbafNews28 gbafNews28
News50 mins ago

Zane Morton to oversee DHL Global Forwarding in New Zealand and Fiji

The logistics veteran brings four decades of DHL experience to the key role in the South Pacific SINGAPORE – Media OutReach –...